aTYR PHARMA INC

ATYR

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001339970

SEC filings (opens in a new tab)

No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding aTYR PHARMA INC changed between Q4 2023 and Q1 2024.

All holders in Q1 2024 All holders in Q4 2023

13F holders of ATYR: Q4 2023 compared with Q1 2024
Measure	Q4 2023	Q1 2024	Change
Holders	46	56	+10
Shares	41.2M	41.8M	+576.1K (+1.4%)
Value	$58.1M	$81.5M	+$23.4M (+40.2%)

New holders (15)

Institutions that held aTYR PHARMA INC at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to ATYR in Q1 2024
Institution	Shares	Value	% of portfolio
Woodline Partners LP	1,681,279	$3.28M	0.03%
Octagon Capital Advisors LP	700,000	$1.36M	0.17%
Ghost Tree Capital, LLC	600,000	$1.17M	0.38%
Marshall Wace, LLP	158,619	$309.3K	0.00%
Jane Street Group, LLC	62,140	$121.2K	0.00%
Kingswood Wealth Advisors, LLC	60,000	$117.0K	0.01%
Jump Financial, LLC	49,904	$97.3K	0.00%
Y-Intercept (Hong Kong) Ltd	43,892	$85.6K	0.01%
Main Street Financial Solutions, LLC	34,475	$67.2K	0.01%
SG Americas Securities, LLC	28,256	$55.0K	0.00%
Schonfeld Strategic Advisors LLC	20,500	$40.0K	0.00%
CTC Alternative Strategies, Ltd.	17,600	$34.3K	0.02%
Two Sigma Securities, LLC	17,487	$34.1K	0.00%
Tower Research Capital LLC (TRC)	6,267	$12.2K	0.00%
Simplex Trading, LLC	6,021	$11.0K	0.00%

Sold out (5)

Institutions that held aTYR PHARMA INC at the end of Q4 2023 and filed for Q1 2024 without it.

Institutions that sold out of ATYR in Q1 2024
Institution	Shares, Q4 2023	Value, Q4 2023
Stonepine Capital Management, LLC	482,258	$680.0K
Squarepoint Ops LLC	119,450	$168.4K
Virtu Financial LLC	26,409	$37.0K
Bank of New York Mellon Corp	16,426	$23.2K
Granite Bay Wealth Management, LLC	18,000	$22.0K